Immune Design Corp. (NASDAQ:IMDZ) shares traded down 3% on Friday . The stock traded as low as $7.54 and last traded at $7.66, with a volume of 87,841 shares. The stock had previously closed at $7.90.

Several research analysts have recently weighed in on the company. Jefferies Group restated a “buy” rating and issued a $20.00 price target on shares of Immune Design Corp. in a research note on Sunday, May 29th. Cowen and Company restated an “outperform” rating on shares of Immune Design Corp. in a research note on Wednesday, April 27th. Leerink Swann restated a “buy” rating on shares of Immune Design Corp. in a research note on Thursday, May 12th. Zacks Investment Research cut Immune Design Corp. from a “hold” rating to a “sell” rating in a research note on Tuesday, July 12th. Finally, Wells Fargo & Co. restated a “buy” rating on shares of Immune Design Corp. in a research note on Wednesday, May 11th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. Immune Design Corp. currently has an average rating of “Buy” and a consensus price target of $24.00.

The stock’s market capitalization is $154.57 million. The company has a 50 day moving average of $8.31 and a 200 day moving average of $11.23.

Immune Design Corp. (NASDAQ:IMDZ) last announced its earnings results on Tuesday, May 10th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.01. On average, equities research analysts forecast that Immune Design Corp. will post ($2.70) EPS for the current fiscal year.

A hedge fund recently raised its stake in Immune Design Corp. stock. Jennison Associates increased its stake in shares of Immune Design Corp. (NASDAQ:IMDZ) by 0.6% during the third quarter, according to its most recent filing with the SEC. The fund owned 202,683 shares of the company’s stock after buying an additional 1,224 shares during the period. Jennison Associates owned 1.01% of Immune Design Corp. worth $2,473,000 at the end of the most recent quarter.

Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.